Tumor necrosis factor (TNF) is being utilized as an antineoplastic agent for the treatment of
patients with locally advanced solid tumors. However, its role in cancer therapy is debated.
Although a large body of evidence supports TNF's antineoplastic activity, the cascade of
molecular events underlying TNF-mediated tumor regression observed in vivo is still
incompletely elucidated. Intriguingly, some pre-clinical findings suggest that TNF may
promote cancer development and progression, which has led to propose anti-TNF therapy …